The world’s most popular coronavirus vaccine, Comirnaty, has received another positive regulatory decision in the USA.
Developed by New York-based pharma giant Pfizer (NYSE: PFE), together with Germany’s BioNTech (Nasdaq: BNTX), the mRNA-based jab has generated tens of billions of dollars in revenue since it was launched at the height of the pandemic.
Since then, the firms have continued investing to develop adapted versions to meet new variants of the virus, as well as to secure approvals for pediatric populations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze